Portable, On-Demand Biomolecular Manufacturing

Cell

Volumn 167, Issue 1, 2016, Pages 248-259.e12

  Pardee, Keith ^a   Slomovic, Shimyn ^b   Nguyen, Peter Q ^c   Lee, Jeong Wook ^b,c   Donghia, Nina ^c   Burrill, Devin ^c   Ferrante, Tom ^c   McSorley, Fern R ^d   Furuta, Yoshikazu ^b   Vernet, Andyna ^c   Lewandowski, Michael ^c   Boddy, Christopher N ^d   Joshi, Neel S ^c,e   Collins, James J ^b,c,f,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e HARVARD UNIVERSITY   (United States)

^f HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

antibody mimetic conjugates; antimicrobial peptides; cell free expression; decentralized biomanufacturing; freeze dried; on demand biosynthesis; portable molecular manufacturing; synthetic biology; vaccine antigens; violacein biosynthetic pathway

Indexed keywords

ANTIMICROBIAL PEPTIDE B1CTCU1; ANTIMICROBIAL PEPTIDE BAC7 (1 35); ANTIMICROBIAL PEPTIDE BP100; ANTIMICROBIAL PEPTIDE CA(1 7)M(2 9); ANTIMICROBIAL PEPTIDE OPISTOPORIN 1; ANTIMICROBIAL PEPTIDE PEP3; ANTIMICROBIAL PEPTIDE TACHYSTATIN A1; CECROPIN B; CECROPIN P1; DIPHTHERIA VACCINE; EXOTOXIN; MAGAININ 2; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VACCINE; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BACILLUS SUBTILIS; CHEMICAL STRUCTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIPHTHERIA; DRUG MANUFACTURE; ESCHERICHIA COLI; HUMAN; IMMUNOFLUORESCENCE; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; SMALLPOX; SYNTHETIC BIOLOGY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; CELL FREE SYSTEM; COMBINATORIAL CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; PROTEIN SYNTHESIS;

ANIMALS; ANTIBODY FORMATION; ANTIMICROBIAL CATIONIC PEPTIDES; CELL-FREE SYSTEM; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; PROTEIN BIOSYNTHESIS; SYNTHETIC BIOLOGY; TRANSCRIPTION, GENETIC; VACCINES;

EID: 84988579147     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.09.013     Document Type: Article

References (73)

1. Adamo, A., Beingessner, R.L., Behnam, M., Chen, J., Jamison, T.F., Jensen, K.F., Monbaliu, J.-C.M., Myerson, A.S., Revalor, E.M., Snead, D.R., et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 352 (2016), 61–67.
2. Amiram, M., Haimovich, A.D., Fan, C., Wang, Y.-S., Aerni, H.-R., Ntai, I., Moonan, D.W., Ma, N.J., Rovner, A.J., Hong, S.H., et al. Evolution of translation machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids. Nat. Biotechnol. 33 (2015), 1272–1279.
3. Balibar, C.J., Walsh, C.T., In vitro biosynthesis of violacein from L-tryptophan by the enzymes VioA-E from Chromobacterium violaceum. Biochemistry 45 (2006), 15444–15457.
4. Botyanszki, Z., Tay, P.K.R., Nguyen, P.Q., Nussbaumer, M.G., Joshi, N.S., Engineered catalytic biofilms: Site-specific enzyme immobilization onto E. coli curli nanofibers. Biotechnol. Bioeng. 112 (2015), 2016–2024.
5. Brito, L.A., Singh, M., Acceptable levels of endotoxin in vaccine formulations during preclinical research. J. Pharm. Sci. 100 (2011), 34–37.
6. Caschera, F., Noireaux, V., Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription-translation system. Biochimie 99 (2014), 162–168.
7. CDC (2016a). Seasonal Influenza Vaccine Effectiveness, 2005-2016; http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm. Accessed August 2016.
8. CDC (2016b). CDC Vaccine Price List: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed August 2016.
9. Chubukov, V., Mukhopadhyay, A., Petzold, C.J., Keasling, J.D., Martín, H.G., Synthetic and systems biology for microbial production of commodity chemicals. Npj Syst. Biol. Appl., 2, 2016, 16009.
10. Collier, R.J. (2006). Multi-mutant diphtheria toxin vaccines. US Patent 7115725 B2.
11. Dandinarasaiah, M., Vikram, B.K., Krishnamurthy, N., Chetan, A.C., Jain, A., Diphtheria Re-emergence: Problems Faced by Developing Countries. Indian J Otolaryngol Head Neck Surg 65 (2013), 314–318.
12. Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J., Bhatia, S.N., Programmable probiotics for detection of cancer in urine. Sci. Transl. Med., 7, 2015, 289ra84.
13. Desmyter, A., Spinelli, S., Roussel, A., Cambillau, C., Camelid nanobodies: killing two birds with one stone. Curr. Opin. Struct. Biol. 32 (2015), 1–8.
14. Dimitrov, D.S., Therapeutic proteins. Methods Mol. Biol. 899 (2012), 1–26.
15. Doshi, R., Chen, B.R., Vibat, C.R.T., Huang, N., Lee, C.-W., Chang, G., In vitro nanobody discovery for integral membrane protein targets. Sci. Rep., 4, 2014, 6760.
16. Dudley, Q.M., Karim, A.S., Jewett, M.C., Cell-free metabolic engineering: biomanufacturing beyond the cell. Biotechnol. J. 10 (2015), 69–82.
17. Ebrahimizadeh, W., Mousavi Gargari, S., Rajabibazl, M., Safaee Ardekani, L., Zare, H., Bakherad, H., Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl. Microbiol. Biotechnol. 97 (2013), 4457–4466.
18. Fernando, G.J.P., Chen, X., Prow, T.W., Crichton, M.L., Fairmaid, E.J., Roberts, M.S., Frazer, I.H., Brown, L.E., Kendall, M.A.F., Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS ONE, 5, 2010, e10266.
19. Fossati, E., Ekins, A., Narcross, L., Zhu, Y., Falgueyret, J.-P., Beaudoin, G.A.W., Facchini, P.J., Martin, V.J.J., Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid dihydrosanguinarine in Saccharomyces cerevisiae. Nat. Commun., 5, 2014, 3283.
20. Garamella, J., Marshall, R., Rustad, M., Noireaux, V., The All E. coli TX-TL Toolbox 2.0: A Platform for Cell-Free Synthetic Biology. ACS Synth. Biol. 5 (2016), 344–355.
21. Gaspar, D., Veiga, A.S., Castanho, M.A.R.B., From antimicrobial to anticancer peptides. A review. Front Microbiol, 4, 2013, 294.
22. Giannini, G., Rappuoli, R., Ratti, G., The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res. 12 (1984), 4063–4069.
23. Gibson, D.G., Young, L., Chuang, R.-Y., Venter, J.C., Hutchison, C.A. 3rd, Smith, H.O., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6 (2009), 343–345.
24. Goerke, A.R., Swartz, J.R., Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol. Bioeng. 99 (2008), 351–367.
25. Green, A.A., Silver, P.A., Collins, J.J., Yin, P., Toehold switches: de-novo-designed regulators of gene expression. Cell 159 (2014), 925–939.
26. Gupta, R.K., Collier, R.J., Rappuoli, R., Siber, G.R., Differences in the immunogenicity of native and formalinized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs. Vaccine 15 (1997), 1341–1343.
27. Hayes, C. (2012). Biomolecular Breadboards:Protocols:cost estimate. http://www.openwetware.org/wiki/Biomolecular_Breadboards:Protocols:cost_estimate. Accessed August 2016.
28. Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J.G., Ng, K.K.-S., MacKenzie, R., Tanha, J., Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286 (2011), 8961–8976.
29. Karim, A.S., Jewett, M.C., A cell-free framework for rapid biosynthetic pathway prototyping and enzyme discovery. Metab. Eng. 36 (2016), 116–126.
30. Kobayashi, H., Kaern, M., Araki, M., Chung, K., Gardner, T.S., Cantor, C.R., Collins, J.J., Programmable cells: interfacing natural and engineered gene networks. Proc. Natl. Acad. Sci. USA 101 (2004), 8414–8419.
31. Kols, A., and Sherris, J. (2000). HPV vaccines: promise and challenges http://www.path.org/files/jsrp13710.pdf. Accessed August 2016.
32. Kontermann, R.E., Dual targeting strategies with bispecific antibodies. MAbs 4 (2012), 182–197.
33. Kumru, O.S., Joshi, S.B., Smith, D.E., Middaugh, C.R., Prusik, T., Volkin, D.B., Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals 42 (2014), 237–259.
34. Kwon, Y.-C., Jewett, M.C., High-throughput preparation methods of crude extract for robust cell-free protein synthesis. Sci. Rep., 5, 2015, 8663.
35. Lee, K.-H., Kwon, Y.-C., Yoo, S.J., Kim, D.-M., Ribosomal synthesis and in situ isolation of peptide molecules in a cell-free translation system. Protein Expr. Purif. 71 (2010), 16–20.
36. Lehar, S.M., Pillow, T., Xu, M., Staben, L., Kajihara, K.K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W.L., Morisaki, J.H., et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 527 (2015), 323–328.
37. Lopes, G. de L. Jr., de Souza, J.A., Barrios, C., Access to cancer medications in low- and middle-income countries. Nat. Rev. Clin. Oncol. 10 (2013), 314–322.
38. Martemyanov, K.A., Shirokov, V.A., Kurnasov, O.V., Gudkov, A.T., Spirin, A.S., Cell-free production of biologically active polypeptides: application to the synthesis of antibacterial peptide cecropin. Protein Expr. Purif. 21 (2001), 456–461.
39. Millet, L.J., Lucheon, J.D., Standaert, R.F., Retterer, S.T., Doktycz, M.J., Modular microfluidics for point-of-care protein purifications. Lab Chip 15 (2015), 1799–1811.
40. Mulligan, M.J., Bernstein, D.I., Frey, S., Winokur, P., Rouphael, N., Dickey, M., Edupuganti, S., Spearman, P., Anderson, E., Graham, I., et al. Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infect. Dis., 1, 2014, ofu102.
41. Ng, C.T., Jaworski, J.P., Jayaraman, P., Sutton, W.F., Delio, P., Kuller, L., Anderson, D., Landucci, G., Richardson, B.A., Burton, D.R., et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16 (2010), 1117–1119.
42. Nguyen, P.Q., Botyanszki, Z., Tay, P.K.R., Joshi, N.S., Programmable biofilm-based materials from engineered curli nanofibres. Nat. Commun., 5, 2014, 4945.
43. Nguyen, P.H.B., Wu, Y., Guo, S., and Murray, R.M. (2015). Design Space Exploration of the Violacein Pathway in Escherichia coli Based Transcription Translation Cell-Free System (TX-TL). bioRxiv.
44. Noireaux, V., Libchaber, A., A vesicle bioreactor as a step toward an artificial cell assembly. Proc. Natl. Acad. Sci. USA 101 (2004), 17669–17674.
45. Palmenberg, A.C., In vitro synthesis and assembly of picornaviral capsid intermediate structures. J. Virol. 44 (1982), 900–906.
46. Pardee, K., Green, A.A., Ferrante, T., Cameron, D.E., DaleyKeyser, A., Yin, P., Collins, J.J., Paper-based synthetic gene networks. Cell 159 (2014), 940–954.
47. Pardee, K., Green, A.A., Takahashi, M.K., Braff, D., Lambert, G., Lee, J.W., Ferrante, T., Ma, D., Donghia, N., Fan, M., et al. Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components. Cell 165 (2016), 1255–1266.
48. Patel, K.G., Ng, P.P., Levy, S., Levy, R., Swartz, J.R., Escherichia coli-based production of a tumor idiotype antibody fragment–tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expr. Purif. 75 (2011), 15–20.
49. Perez-Pinera, P., Han, N., Cleto, S., Cao, J., Purcell, O., Shah, K.A., Lee, K., Ram, R., Lu, T.K., Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care. Nat. Commun., 7, 2016, 12211.
50. Plückthun, A., Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55 (2015), 489–511.
51. Ryabova, L.A., Desplancq, D., Spirin, A.S., Plückthun, A., Functional antibody production using cell-free translation: effects of protein disulfide isomerase and chaperones. Nat. Biotechnol. 15 (1997), 79–84.
52. Salehi, A.S.M., Smith, M.T., Bennett, A.M., Williams, J.B., Pitt, W.G., Bundy, B.C., Cell-free protein synthesis of a cytotoxic cancer therapeutic: Onconase production and a just-add-water cell-free system. Biotechnol. J. 11 (2016), 274–281.
53. Sánchez, C., Braña, A.F., Méndez, C., Salas, J.A., Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis. ChemBioChem 7 (2006), 1231–1240.
54. Schwendeman, S.P., Costantino, H.R., Gupta, R.K., Siber, G.R., Klibanov, A.M., Langer, R., Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl. Acad. Sci. USA 92 (1995), 11234–11238.
55. Scott, A.M., Wolchok, J.D., Old, L.J., Antibody therapy of cancer. Nat. Rev. Cancer 12 (2012), 278–287.
56. Setia, S., Mainzer, H., Washington, M.L., Coil, G., Snyder, R., Weniger, B.G., Frequency and causes of vaccine wastage. Vaccine 20 (2002), 1148–1156.
57. Smith, M.T., Berkheimer, S.D., Werner, C.J., Bundy, B.C., Lyophilized Escherichia coli-based cell-free systems for robust, high-density, long-term storage. Biotechniques 56 (2014), 186–193.
58. Spirin, A.S., Baranov, V.I., Ryabova, L.A., Ovodov, S.Y., Alakhov, Y.B., A continuous cell-free translation system capable of producing polypeptides in high yield. Science 242 (1988), 1162–1164.
59. Sullivan, C.J., Pendleton, E.D., Sasmor, H.H., Hicks, W.L., Farnum, J.B., Muto, M., Amendt, E.M., Schoborg, J.A., Martin, R.W., Clark, L.G., et al. A cell-free expression and purification process for rapid production of protein biologics. Biotechnol. J. 11 (2016), 238–248.
60. Sun, Z.Z., Hayes, C.A., Shin, J., Caschera, F., Murray, R.M., Noireaux, V., Protocols for implementing an Escherichia coli based TX-TL cell-free expression system for synthetic biology. J. Vis. Exp., 79, 2013, e50762.
61. Swartz, J., Developing cell-free biology for industrial applications. J. Ind. Microbiol. Biotechnol. 33 (2006), 476–485.
62. Torella, J.P., Gagliardi, C.J., Chen, J.S., Bediako, D.K., Colón, B., Way, J.C., Silver, P.A., Nocera, D.G., Efficient solar-to-fuels production from a hybrid microbial-water-splitting catalyst system. Proc. Natl. Acad. Sci. USA 112 (2015), 2337–2342.
63. Wan, W., Wang, D., Gao, X., Hong, J., Expression of family 3 cellulose-binding module (CBM3) as an affinity tag for recombinant proteins in yeast. Appl. Microbiol. Biotechnol. 91 (2011), 789–798.
64. Wang, R.E., Liu, T., Wang, Y., Cao, Y., Du, J., Luo, X., Deshmukh, V., Kim, C.H., Lawson, B.R., Tremblay, M.S., et al. An immunosuppressive antibody-drug conjugate. J. Am. Chem. Soc. 137 (2015), 3229–3232.
65. Welsh, J.P., Lu, Y., He, X.-S., Greenberg, H.B., Swartz, J.R., Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens. Biotechnol. Bioeng. 109 (2012), 2962–2969.
66. WHO (2014a). Temperature Sensitivity of Vaccines; http://www.who.int/immunization/programmes_systems/supply_chain/resources/VaccineStability_EN.pdf. Accessed August 2016.
67. WHO (2014b). World Health Organization: Information sheet observed rate of vaccine reactions Diphtheria, pertussis, tetanus vaccines. http://www.who.int/vaccine_safety/initiative/tools/DTP_vaccine_rates_information_sheet.pdf. Accessed August 2016.
68. Wolf, P., Elsässer-Beile, U., Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 299 (2009), 161–176.
69. Wolfson, L.J., Gasse, F., Lee-Martin, S.-P., Lydon, P., Magan, A., Tibouti, A., Johns, B., Hutubessy, R., Salama, P., Okwo-Bele, J.-M., Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull. World Health Organ. 86 (2008), 27–39.
70. Zakeri, B., Fierer, J.O., Celik, E., Chittock, E.C., Schwarz-Linek, U., Moy, V.T., Howarth, M., Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 109 (2012), E690–E697.
71. Zawada, J.F., Yin, G., Steiner, A.R., Yang, J., Naresh, A., Roy, S.M., Gold, D.S., Heinsohn, H.G., Murray, C.J., Microscale to manufacturing scale-up of cell-free cytokine production–a new approach for shortening protein production development timelines. Biotechnol. Bioeng. 108 (2011), 1570–1578.
72. Zhang, Y.-H.P., Cui, J., Lynd, L.R., Kuang, L.R., A transition from cellulose swelling to cellulose dissolution by o-phosphoric acid: evidence from enzymatic hydrolysis and supramolecular structure. Biomacromolecules 7 (2006), 644–648.
73. Zichel, R., Mimran, A., Keren, A., Barnea, A., Steinberger-Levy, I., Marcus, D., Turgeman, A., Reuveny, S., Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin. Vaccine Immunol. 17 (2010), 784–792.